
Cytokinetics, Incorporated CYTK
$ 63.82
0.65%
Quarterly report 2025-Q3
added 11-05-2025
Cytokinetics, Incorporated Cash Conversion Cycle 2011-2026 | CYTK
Annual Cash Conversion Cycle Cytokinetics, Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 | 34.7 | 100 | 146 | 31.3 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 | 31.3 | 97.8 |
Quarterly Cash Conversion Cycle Cytokinetics, Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 241 | 7.12 | 65.2 | - | - | - | 421 | 105 | 11.4 | - | 41.6 | 3.11 | 2.3 K | - | 28.1 | 116 | 62.2 | - | 9.67 | 112 | 114 | - | 77.8 | 66 | 39.9 | - | 19.1 | 32.8 | 28.9 | -5.64 K | 16.4 | 33.2 | 12.5 | 0.07 | 0.04 | 0.19 | 1.08 | 0.94 | - | - | 1.13 | 0.23 | - | - | 1.23 | 0.4 | - | - | 10.4 | 3.91 | - | - | 5.16 | 12.4 | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.3 K | -5.64 K | -43.1 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Adagene
ADAG
|
53.8 | $ 2.4 | -3.61 % | $ 135 M | ||
|
Aptorum Group Limited
APM
|
-400 | $ 0.97 | 0.81 % | $ 5.29 M | ||
|
Biogen
BIIB
|
387 | $ 172.5 | 0.53 % | $ 25.1 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Catalyst Biosciences
CBIO
|
391 | $ 12.1 | -5.47 % | $ 797 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Cellectis S.A.
CLLS
|
-839 | $ 4.16 | -5.88 % | $ 116 M | ||
|
BioXcel Therapeutics
BTAI
|
-2.28 K | $ 1.79 | -1.92 % | $ 4.54 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 67.09 | 0.06 % | $ 8.97 B | ||
|
Compugen Ltd.
CGEN
|
-123 | $ 2.05 | -2.15 % | $ 184 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 26.4 | 1.85 % | $ 1.28 B | ||
|
Coherus BioSciences
CHRS
|
326 | $ 2.27 | 10.19 % | $ 214 M | ||
|
Amneal Pharmaceuticals
AMRX
|
123 | $ 13.54 | 1.12 % | $ 4.18 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Celldex Therapeutics
CLDX
|
-6.08 K | $ 26.48 | 2.16 % | $ 1.71 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.73 | 1.11 % | $ 17.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
-58 | $ 94.12 | 1.25 % | $ 96.9 B | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B |